Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Döhner

Showing results (71-80 of 490) with videos related to

Pageof 49
Sort By:
Blood|July 15, 2006
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BStefan Fröhling, Richard F Schlenk, Sabine Kayser, et al.
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2005
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignanciesStefan Reuter, Winfried V Kern, Anja Sigge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation statusChristian Haslinger, Norbert Schweifer, Stephan Stilgenbauer, et al.
British Journal of Haematology|December 8, 2009
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cellsIrina Idler, Krzysztof Giannopoulos, Thorsten Zenz, et al.
Molecular Cancer|March 19, 2013
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoformsKerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutationSusanne Hofmann, Marlies Götz, Vanessa Schneider, et al.
Blood|August 10, 2013
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)Jochen Greiner, Vanessa Schneider, Michael Schmitt, et al.
International Journal of Oncology|October 4, 2007
Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent mannerJinfei Chen, Anita Schmitt, Krzysztof Giannopoulos, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 26, 2006
Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphomaArmin Pscherer, Julia Schliwka, Kathrin Wildenberger, et al.
Pageof 49

Showing results (71-80 of 490) with videos related to

Sort By:
Pageof 49
Blood|July 15, 2006
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-BStefan Fröhling, Richard F Schlenk, Sabine Kayser, et al.
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2005
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignanciesStefan Reuter, Winfried V Kern, Anja Sigge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation statusChristian Haslinger, Norbert Schweifer, Stephan Stilgenbauer, et al.
British Journal of Haematology|December 8, 2009
Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cellsIrina Idler, Krzysztof Giannopoulos, Thorsten Zenz, et al.
Molecular Cancer|March 19, 2013
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoformsKerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutationSusanne Hofmann, Marlies Götz, Vanessa Schneider, et al.
Blood|August 10, 2013
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)Jochen Greiner, Vanessa Schneider, Michael Schmitt, et al.
International Journal of Oncology|October 4, 2007
Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent mannerJinfei Chen, Anita Schmitt, Krzysztof Giannopoulos, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 26, 2006
Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphomaArmin Pscherer, Julia Schliwka, Kathrin Wildenberger, et al.
Pageof 49